



## MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020

August 7, 2020

WESTLAKE VILLAGE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 at 2:00 pm (ET). Interested parties can access a link to the live webcast of the presentation from the Events & Presentations section of the Company's website at <http://www.mannkindcorp.com>. The webcast replay will remain available for 14 days following the live presentation.

### About MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit [www.mannkindcorp.com](http://www.mannkindcorp.com).

### Company Contact:

818-661-5000

[ir@mannkindcorp.com](mailto:ir@mannkindcorp.com)



Source: MannKind